FIELD: chemistry.
SUBSTANCE: invention relates to novel amide derivatives of formula (I), isomers and pharmaceutically acceptable salt thereof, which have cancer cell selective inhibiting properties, caused by an epidermal growth factor receptor (EGFR), selected from EGFR or caused by EGFR mutation. In formula (I): (I) (a) or (b), A denotes a group (a) or (b), R4, R5, R6 and R7, each independently denote hydrogen, halogen, N-C1-6alkyl or N-hydroxyamido or inverse C-C1-6alkylamido (-NHCOC1-6alkyl), hydroxycarbonyl(-COOH), C1-6 alkyloxycarbonyl(-COOC1-6), C1-6alkyl or C1-6alkyl, substituted with a hydroxy group, C1-6dialkylamino or a saturated 5-6-member heterocyclic group with 1-2 heteroatoms and selected from nitrogen and oxygen atoms; R1 denotes a phenyl or a 6-member heteroaryl group with a nitrogen atom as a heteroatom, each of which is substituted with 1-3 X, or C1-6alkyl, substituted with a phenyl, which can be substituted with halogen atoms; R2 denotes hydrogen, hydroxy, C1-6alkoxy or C1-6alkoxy, substituted C1-6alkoxy or 5-6-member saturated heterocyclic group; R3 denotes hydrogen, -COOH, C1-6alkyloxycarbonyl or amido, N-unsubstituted or N-substituted Y; na and nb each is a whole number ranging from 1 to 3; where: X denotes hydrogen, halogen, hydroxy, cyano, nitro, (mono-, di- or trihalogen)methyl, mercapto, C1-6alkylthio, acrylamido, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C1-6alkoxy, phenyloxy, C1-6dialkylamino or C1-6alkyl or C1-6alkoxy, substituted with Z, provided that when the number of substitutes X equals two or more, groups X can be condensed with each other to form a 5-member cyclic structure, possibly containing 2 nitrogen atoms in the ring as heteroatoms; Y denotes hydroxy, C1-6alkyl or C1-6alkyl substituted with Z, C1-6alkyl has 1-4 fragments selected from a group consisting of N, O, S, SO and SO2; and Z denotes C1-6alkyl, phenyl or a 6-member heterocyclic group containing one or more heteroatoms selected from N or O. Said phenyl or heterocyclic group is unsubstituted or substituted with a halogen.
EFFECT: improved properties of the derivatives.
4 cl, 7 tbl, 144 ex
Title | Year | Author | Number |
---|---|---|---|
QUINAZOLINE DERIVATIVES FOR SLOWING DOWN GROWTH OF CANCER CELLS AND METHOD OF OBTAINING THEM | 2005 |
|
RU2362773C2 |
NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2585177C2 |
METHOD OF OBTAINING HYDROCHLORIDE OF 1-(3,4-DICHLORO-2-FLUOROPHENYLAMINO)-7-METHOXYQUINAZOLIN-6-YLOXY)PIPERIDIN-1-YL)PROP-2-EN-1-ONE AND INTERMEDIATE COMPOUNDS, APPLIED IN IT | 2012 |
|
RU2563630C1 |
THIENO[3,2-d]PYRIMIDINE DERIVATIVES, POSSESSING INHIBITING ACTION WITH RESPECT TO PROTEINKINASE | 2011 |
|
RU2524210C2 |
ORALLY BIOAVAILABLE PRODRUGS OF (+)-3-HYDROXYMORPHINAN FOR PREVENTING OR TREATING PARKINSON'S DISEASE | 2008 |
|
RU2430089C2 |
PYRAZOLOPYRIMIDINE DERIVATIVES AS A KINASE INHIBITOR | 2017 |
|
RU2714206C1 |
ANTIINFECTIVE COMPOUNDS | 2011 |
|
RU2576662C2 |
NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | 2011 |
|
RU2598852C2 |
GLUCOKINASE ACTIVATORS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AS ACTIVE INGREDIENT | 2008 |
|
RU2450001C2 |
NEW PYRIDINE DERIVATIVES, METHOD FOR MAKING THEREOF AND RELATED PHARMACEUTICAL COMPOSITION | 2004 |
|
RU2366659C2 |
Authors
Dates
2011-11-20—Published
2008-06-05—Filed